Drug intelligence / Profile preview

OVV-02

Development stage: Preclinical
Lead developer: Li Ning
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intravenous, Intratumoral

Overview

OVV-02 is a CD19-directed oncolytic vesicular stomatitis virus (VSV) being developed by Joint Biosciences for the treatment of solid tumors. The therapeutic is designed to selectively infect and lyse tumor cells that express CD19, while simultaneously inducing a systemic antitumor immune response. By targeting CD19, a well-validated antigen in hematological malignancies, OVV-02 aims to extend the utility of CD19-targeted therapies to solid tumor indications. It is currently in the preclinical stage of development.

Other names: VSV-CD19VSV-CD-19VSV-CD 19

Targets

CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on OVV-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVV-02.

Explore the full profile